S.Amdt. 3781Senate115th Congress (2017-2019)
S.Amdt. 3781
Sponsored by
Sen. Benjamin L. Cardin (D-MD)
Submitted August 20, 2018
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Floor
Latest Action
Senate amendment submitted
August 20, 2018
Text
Submitted
SA 3781. Mr. CARDIN submitted an amendment intended to be proposed by him to the bill H.R. 6157, making appropriations for the Department of Defense for the fiscal year ending September 30, 2019, and for other purposes; which was ordered to lie on the table; as follows: At the appropriate place in title II of division B, insert the following: SEC. __. HHS STUDY ON DRUG PRICING. (a) Study.--The Secretary of Health and Human Services (in this section referred to as the ``Secretary'') shall conduct a study on the changes in prices of prescription drugs since 2008. Such study shall include the following: (1) A comparison of prescription drug prices (net of rebates) paid by the following programs for the 10 most frequently prescribed drugs and the 10 highest-cost drugs for each of the following: (A) The Medicare program under part B of title XVIII of the Social Security Act. (B) The Medicare prescription drug program under part D of title XVIII of such Act. (C) The Medicaid program under title XIX of such Act. (D) The Department of Veterans Affairs. (2) A breakdown of the comparative prices (net of rebates) for each of the 10 most frequently prescribed drugs and the 10 highest-cost drugs between ambulatory settings and retail settings. (3) Under the Medicare prescription drug program under such part D, a description of the gross drug costs and net drug costs and the direct and indirect remuneration for the 10 most frequently prescribed drugs and the 10 highest-cost drugs. (4) A description of the total annual costs due to prescription drugs under the Medicare program under such part B, such part D, and the Medicaid program. (5) A list the drugs that have been registered for sale by the Food and Drug Administration in the past 5 years that have benefited significantly from government grants or research subsidies in either the pre-clinical or clinical stages of development, as well as the price (net of rebates) and total spending under the Medicare and Medicaid programs for each of those drugs. (6) Other items determined appropriate by the Secretary. (b) Report.--Not later than 120 days after the date of enactment of this Act, the Secretary shall submit to Congress a report on [[Page S5730]] the study conducted under subsection (a), together with recommendations for such legislation and administrative action as the Secretary determines appropriate. ______